Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PTEN inact mut |
| Therapy | AZD8186 + Docetaxel |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PTEN inact mut | Advanced Solid Tumor | no benefit | AZD8186 + Docetaxel | Phase I | Actionable | In a Phase I trial, treatment with the combination of AZD8186 and Taxotere (docetaxel) was generally well tolerated but demonstrated limited efficacy with an overall response rate of 5.6% (1/18), clinical benefit rate of 22.2% (4/18), and median progression-free survival of 3 months in patients with advanced solid tumors harboring PTEN inactivating mutations (n=21) or PIK3CB activating mutations (n=3) (PMID: 40939237; NCT03218826). | 40939237 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (40939237) | A phase I study of AZD8186 in combination with docetaxel in patients with PTEN-mutated or PIK3CB-mutated advanced solid tumors. | Full reference... |